Insmed Inc INSM
We take great care to ensure that the data presented and summarized in this overview for INSMED Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSM
View all-
Jpmorgan Chase & CO New York, NY23MShares$4.45 Billion0.22% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y920.5MShares$3.95 Billion89.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.9MShares$3.85 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY14.3MShares$2.76 Billion0.02% of portfolio
-
Capital International Investors Los Angeles, CA7.55MShares$1.46 Billion0.18% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.93MShares$1.34 Billion0.11% of portfolio
-
Baker Bros. Advisors LP New York, NY6.7MShares$1.3 Billion7.86% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.66MShares$1.09 Billion0.52% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.94MShares$954 Million1.09% of portfolio
-
State Street Corp Boston, MA3.98MShares$770 Million0.02% of portfolio
Latest Institutional Activity in INSM
Top Purchases
Top Sells
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at INSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
10,699
-0.86%
|
$2,203,994
$206.05 P/Share
|
|
Dec 04
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,699
+1.68%
|
$246,077
$23.81 P/Share
|
|
Dec 01
2025
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,895
-3.31%
|
$1,832,370
$206.91 P/Share
|
|
Dec 01
2025
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,895
+8.82%
|
$222,375
$25.83 P/Share
|
|
Nov 24
2025
|
Elizabeth M Anderson Director |
SELL
Open market or private sale
|
Direct |
5,000
-7.85%
|
$1,020,000
$204.58 P/Share
|
|
Nov 17
2025
|
Leo Lee Director |
SELL
Open market or private sale
|
Direct |
75,000
-15.49%
|
$14,625,000
$195.48 P/Share
|
|
Nov 14
2025
|
Elizabeth M Anderson Director |
SELL
Open market or private sale
|
Direct |
10,000
-13.56%
|
$1,950,000
$195.87 P/Share
|
|
Nov 12
2025
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
SELL
Open market or private sale
|
Direct |
30,000
-12.87%
|
$5,820,000
$194.1 P/Share
|
|
Nov 12
2025
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+31.1%
|
$780,000
$26.46 P/Share
|
|
Nov 11
2025
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
31,226
-7.6%
|
$5,901,714
$189.78 P/Share
|
|
Nov 11
2025
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,226
+12.83%
|
$562,068
$18.01 P/Share
|
|
Nov 06
2025
|
David R Brennan Director |
BUY
Bona fide gift
|
Indirect |
60,000
+50.0%
|
-
|
|
Nov 06
2025
|
David R Brennan Director |
SELL
Bona fide gift
|
Direct |
60,000
-47.27%
|
-
|
|
Nov 03
2025
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
27,130
-4.87%
|
$4,991,920
$184.42 P/Share
|
|
Nov 03
2025
|
Michael Alexander Smith Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,130
+24.85%
|
$623,990
$23.75 P/Share
|
|
Sep 12
2025
|
Melvin Md Sharoky Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.67%
|
$1,450,000
$145.39 P/Share
|
|
Sep 12
2025
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
SELL
Open market or private sale
|
Direct |
76,520
-23.94%
|
$11,171,920
$146.08 P/Share
|
|
Sep 12
2025
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,520
+33.34%
|
$1,299,960
$23.75 P/Share
|
|
Sep 11
2025
|
Melvin Md Sharoky Director |
BUY
Bona fide gift
|
Direct |
159
+0.06%
|
-
|
|
Sep 11
2025
|
Melvin Md Sharoky Director |
SELL
Bona fide gift
|
Indirect |
159
-17.67%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 638K shares |
|---|---|
| Exercise of conversion of derivative security | 1.21M shares |
| Bona fide gift | 67.6K shares |
| Open market or private purchase | 3.03K shares |
| Open market or private sale | 2.06M shares |
|---|---|
| Bona fide gift | 109K shares |